MedTrace Logo

Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)

NCT04901325 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-05-13

No results posted yet for this study

Summary

An Open-Label, Proof-Of-Concept, Study of Baricitinib for the Treatment of Pyoderma Gangrenosum

Conditions

  • Pyoderma Gangrenosum
  • Skin Diseases
  • Wound Heal
  • Pyoderma
  • Skin Ulcer

Interventions

DRUG

Baricitinib

Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks.

Sponsors & Collaborators

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Alex G Ortega-Loayza, MD, MCR · Oregon Health & Science University, Department of Dermatology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-03
Primary Completion
2025-01-05
Completion
2025-05-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04901325 on ClinicalTrials.gov